NCT00045864已完成2 期
Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 65
研究概览
简要总结
The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade Non-Hodgkin's lymphoma.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis: CD20+ B-cell non-Hodgkin's lymphoma (NHL) classified as intermediate- or high-grade according to the Working Formulation, subtypes D to H. Must have measureable progressive or refractory disease after no more than three prior chemotherapy regimens.
排除标准
- •Clinically significant cardiac dysfunction, or a history of myocardial infarction or heart failure within 6 months of first study treatment
- •Clinically significant pulmonary dysfunction.
- •Liver disease (note hepatitis C seropositive subjects may be enrolled if they have no active disease as demonstrated by undetectable HCV viral loads, biopsy showing no active disease, and/or history of normal transaminases on at least three different dates within one year of first study treatment).
- •Symptomatic thyroid disease requiring medical intervention other than replacement treatment for hypothyroidism.
- •History of autoimmune disease.
- •History of positive serology for human immunodeficiency virus (HIV).
研究者
研究点 (65)
Loading locations...
相似试验
已完成
2 期
Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan TreatmentsLymphoma, Non-HodgkinNCT00045877Chiron Corporation
Unknown
2 期
Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant MelanomaMalignant Melanoma of Skin Stage IIIMetastatic MelanomaNCT02142335California Cancer Assocaties for Research & Excellence17
已完成
1 期
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast CancerBreast CarcinomaHER-2 Positive Breast CancerMetastatic Breast CancerNCT02066532Dawn L. Hershman32
已完成
2 期
A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin LymphomaRelapsed/Refractory Indolent B Cell Non-Hodgkin LymphomasNCT02086175Dana-Farber Cancer Institute25
Unknown
2 期
Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell LymphomaLymphoma, B-CellNCT04246359Huiqiang Huang52